Anton Drollmann
Altana
9 Papers
231 Citations
Anton Drollmann is an academic researcher from Altana. The author has contributed to research in topics: Ciclesonide & Active metabolite. The author has an hindex of 8, co-authored 9 publications.
Chat about Author
Papers
Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide.
Anita Weinbrenner,Dagny Hüneke,Zschiesche M,Georg P. Engel,Wolfgang Timmer,Volker W. Steinijans,T.D. Bethke,Wilhelm Wurst,Anton Drollmann,Hans Joachim Kaatz,Werner Siegmund +10 more
TL;DR: In conclusion, inhaled ciclesonide in daily doses of 800 microg for 7 d is without clinically relevant effects on the hypothalamic-pituitary-adrenal axis independent of the time of administration.
Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma
TL;DR: Ciclesonide 80 and 320 microg administered once daily was a safe and effective maintenance treatment for patients with persistent asthma and no cortisol suppression was observed.
56
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma.
Boulet Lp,Anton Drollmann,P. Magyar,M. Timar,A. Knight,Renate Engelstätter,Leonardo M. Fabbri +6 more
TL;DR: Ciclesonide 320 microg once daily by HFA-MDI without a spacer was at least as effective as budesonide 320 microscopic once daily in persistent asthma.
51
Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin.
Ruediger Nave,Anton Drollmann,Volker W. Steinijans,K Zech,T.D. Bethke +4 more
- 01 Jun 2005
TL;DR: Combined administration of ciclesonide and erythromycin did not alter the pharmacokinetics (PK) of either drug and both drugs were safe and well-tolerated, suggesting systemic exposure to cicleonide or erystromycin is not increased in patients receiving concomitant therapy.
17
Effect of Coadministered Ketoconazole, a Strong Cytochrome P450 3A4 Enzyme Inhibitor, on the Pharmacokinetics of Ciclesonide and its Active Metabolite Desisobutyryl-Ciclesonide
TL;DR: The CYP3A4 pathway is the major pathway for biotransformation of the active metabolite of ciclesonide in humans and dose adjustment is not necessary when cicles onide needs to be coadministered with ketoconazole, because the potency of an inhaled corticosteroid is mediated by topical concentrations in the lung and cicleonide has a very low potential to produce systemic adverse effects.
15